| Literature DB >> 25181531 |
Abstract
BACKGROUND &Entities:
Mesh:
Substances:
Year: 2014 PMID: 25181531 PMCID: PMC4152273 DOI: 10.1371/journal.pone.0106397
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Current Firehose data content (Some of these data may not be accessible due to TCGA data restrictions, full data table can be accessible via http://gdac.broadinstitute.org/runs/stddata__2014_03_16/ingested_data.html).
| Cohort | Clinical | CN | Methylation | mRNA | mRNASeq | miR | miRSeq | RPPA | MAF |
| ACC | 15 | 90 | 80 | 0 | 79 | 0 | 80 | 0 | 90 |
| BLCA | 198 | 252 | 242 | 0 | 241 | 0 | 241 | 127 | 130 |
| BRCA | 981 | 1041 | 1024 | 526 | 1037 | 0 | 1021 | 408 | 976 |
| CESC | 127 | 192 | 189 | 0 | 185 | 0 | 200 | 0 | 39 |
| COAD | 436 | 427 | 434 | 153 | 432 | 0 | 406 | 331 | 154 |
| COADREAD | 604 | 589 | 596 | 222 | 595 | 0 | 549 | 461 | 223 |
| DLBC | 21 | 28 | 28 | 0 | 28 | 0 | 27 | 0 | 0 |
| ESCA | 39 | 97 | 93 | 0 | 0 | 0 | 72 | 0 | 0 |
| GBM | 578 | 570 | 414 | 540 | 160 | 565 | 0 | 214 | 290 |
| HNSC | 408 | 509 | 457 | 0 | 497 | 0 | 512 | 212 | 306 |
| KICH | 93 | 66 | 66 | 0 | 66 | 0 | 66 | 0 | 66 |
| KIRC | 507 | 514 | 511 | 72 | 518 | 0 | 502 | 454 | 417 |
| KIRP | 164 | 182 | 198 | 16 | 172 | 0 | 198 | 0 | 168 |
| LAML | 200 | 197 | 194 | 0 | 179 | 0 | 188 | 0 | 197 |
| LGG | 305 | 463 | 403 | 27 | 463 | 0 | 438 | 258 | 289 |
| LIHC | 151 | 190 | 194 | 0 | 191 | 0 | 200 | 0 | 0 |
| LUAD | 466 | 493 | 555 | 32 | 488 | 0 | 491 | 237 | 229 |
| LUSC | 411 | 490 | 492 | 154 | 489 | 0 | 467 | 195 | 178 |
| MESO | 13 | 37 | 37 | 0 | 0 | 0 | 0 | 0 | 0 |
| OV | 580 | 576 | 584 | 574 | 296 | 570 | 453 | 412 | 316 |
| PAAD | 73 | 91 | 91 | 0 | 85 | 0 | 85 | 0 | 91 |
| PCPG | 10 | 0 | 179 | 0 | 0 | 0 | 0 | 0 | 0 |
| PRAD | 199 | 331 | 336 | 0 | 297 | 0 | 326 | 164 | 261 |
| READ | 168 | 162 | 162 | 69 | 163 | 0 | 143 | 130 | 69 |
| SARC | 102 | 137 | 170 | 0 | 103 | 0 | 136 | 0 | 0 |
| SKCM | 341 | 385 | 374 | 0 | 372 | 0 | 354 | 205 | 344 |
| STAD | 311 | 352 | 373 | 0 | 274 | 0 | 323 | 264 | 221 |
| THCA | 484 | 494 | 496 | 0 | 494 | 0 | 495 | 222 | 402 |
| UCEC | 482 | 525 | 532 | 54 | 527 | 0 | 513 | 200 | 248 |
| UCS | 57 | 56 | 57 | 0 | 57 | 0 | 56 | 0 | 57 |
| Totals | 7920 | 8947 | 8965 | 2217 | 7893 | 1135 | 7993 | 4033 | 5538 |
Figure 1Overall RTCGAToolbox structure and workflow.
(A) Overall representation of RTCGAToolbox layers from Firehose web portal to user environments. (B) Sample workflow for “BRCA” dataset.
Data types supported by RTCGAToolbox.
| Data Type (Parameter) | Description | Output Object (FirehoseData) |
|
| Provides clinical information for each sample. Clinical information may include stage, survival time, sex, age and more. |
|
|
| Gene level expression data from RNA-seq platforms. This parameter provides raw counts and normalized values. Firehose provides 2 different algorithms for RNAseq data processing. (Data types can be specified by using RNAseqNorm and RNAseq2Norm parameters) |
|
|
| miRNA expression levels from next generation sequencing platforms |
|
|
| Segmented copy number alterations (in somatic cells) |
|
|
| Segmented copy number variations (in germline cells) |
|
|
| Copy number alterations provided by next generation sequencing platforms |
|
|
| Copy number alterations provided by CGH array platforms |
|
|
| Methylation data provided by array platforms |
|
|
| Gene level mutation information matrix |
|
|
| Gene level expression data provided by array platforms |
|
|
| miRNA expression data provided by array platforms |
|
|
| Reverse phase protein array (RPPA) expression |
|
Figure 2Sample heatmap outputs from BRCA dataset.
Panel A and B show the top differentially up and down regulated genes between “Cancer” and “Normal” samples by using RNASeq and microarray data respectively.
Figure 3KM plot for PIK3CA gene.
A KM plot that compares the survival difference between PIK3CA, which is the gene has highest mutation frequency in BRCA dataset, high and low expressed samples.
Figure 4Summary plot for BRCA dataset.
A circle plot that shows the differentially expressed genes result from RNASeq and microarray platform (Inner circle 1 and 2, y axis represents the fold change value, red dots are up regulated and blue dots are down regulated in cancer samples), copy number changes (inner third circle, blue zones represents the deletions and red circle represents the amplifications) and outer circle shows the genes that has mutation at least 5% of samples.